Premium
Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base
Author(s) -
Kharod Shivam M.,
Indelicato Daniel J.,
Rotondo Ronny L.,
Mailhot Vega Raymond B.,
Uezono Haruka,
Morris Christopher G.,
Bradfield Scott,
Sandler Eric S.,
Bradley Julie A.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28080
Subject(s) - medicine , skull , sarcoma , common terminology criteria for adverse events , surgery , ewing's sarcoma , base of skull , radiation therapy , radiology , chemotherapy , pathology
Purpose Despite the dosimetric advantages of proton therapy, little data exist on patients who receive proton therapy for Ewing sarcoma of the cranium and skull base. This study reports local disease control and toxicity in such patients. Materials/methods We reviewed 25 patients (≤21 years old) with nonmetastatic Ewing sarcoma of the cranium and skull base treated between 2008 and 2018. Treatment toxicity was graded per the Common Terminology Criteria for Adverse Events v4.0. The Kaplan‐Meier product limit method provided estimates of disease control and survival. Results Median patient age was 5.9 years (range, 1–21.7). Tumor subsites included the skull base (48%), non‐skull‐base calvarial bones (28%), paranasal sinuses (20%), and nasal cavity (4%). All patients underwent multiagent alkylator‐ and anthracycline‐based chemotherapy; 16% underwent gross total resection (GTR) before radiation. Clinical target volume (CTV) 1 received 45 GyRBE and CTV2 received 50.4 GyRBE following GTR or 54–55.8 GyRBE following biopsy or subtotal resection. Median follow‐up was 3.7 years (range, 0.26–8.3); no patients were lost. The 4‐year local control, disease‐free survival, and overall survival rates were 96%, 86%, and 92%, respectively. Two patients experienced in‐field recurrences. One patient experienced bilateral conductive hearing loss requiring aids, two patients developed intracranial vasculopathy, and 6 patients required hormone replacement therapy for neuroendocrine deficits. None developed a secondary malignancy. Conclusion Proton therapy is associated with a favorable therapeutic ratio in children with large Ewing tumors of the cranium and skull base. Despite its high conformality, we observed excellent local control and no marginal recurrences. Treatment dosimetry predicts limited long‐term neurocognitive and neuroendocrine side effects.